Zacks Research Issues Negative Estimate for Hologic Earnings

Hologic, Inc. (NASDAQ:HOLX) – Investment analysts at Zacks Research decreased their Q3 2026 earnings per share (EPS) estimates for shares of Hologic in a research report issued on Monday, November 24th. Zacks Research analyst Team now anticipates that the medical equipment provider will post earnings of $1.12 per share for the quarter, down from their prior forecast of $1.13. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic’s Q4 2026 earnings at $1.18 EPS, Q3 2027 earnings at $1.22 EPS and Q4 2027 earnings at $1.23 EPS.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same quarter in the prior year, the firm posted $1.01 earnings per share. The business’s quarterly revenue was up 6.2% compared to the same quarter last year.

Other equities analysts also recently issued reports about the stock. Mizuho downgraded shares of Hologic from an “outperform” rating to a “neutral” rating and upped their price objective for the company from $70.00 to $78.00 in a research note on Thursday, October 23rd. Leerink Partners boosted their price target on Hologic from $70.00 to $78.00 and gave the company a “market perform” rating in a report on Tuesday, October 21st. Raymond James Financial cut Hologic from a “moderate buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Wall Street Zen cut Hologic from a “buy” rating to a “hold” rating in a research note on Wednesday, October 1st. Finally, UBS Group upped their target price on Hologic from $65.00 to $70.00 and gave the company a “neutral” rating in a report on Thursday, July 31st. Five analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $79.67.

Hologic Trading Down 0.1%

NASDAQ:HOLX opened at $74.80 on Thursday. The firm has a market capitalization of $16.67 billion, a P/E ratio of 31.04, a P/E/G ratio of 2.54 and a beta of 0.65. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. The company has a fifty day moving average of $71.17 and a 200 day moving average of $66.79. Hologic has a 52 week low of $51.90 and a 52 week high of $80.31.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of HOLX. The Manufacturers Life Insurance Company lifted its stake in shares of Hologic by 294.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock worth $718,223,000 after purchasing an additional 8,227,318 shares during the period. Invesco Ltd. raised its position in Hologic by 72.5% in the second quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after acquiring an additional 3,505,828 shares during the period. Geode Capital Management LLC boosted its stake in shares of Hologic by 1.7% during the 2nd quarter. Geode Capital Management LLC now owns 5,828,325 shares of the medical equipment provider’s stock worth $378,209,000 after acquiring an additional 97,142 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Hologic by 1.6% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider’s stock valued at $276,303,000 after acquiring an additional 69,878 shares during the period. Finally, Black Creek Investment Management Inc. increased its stake in shares of Hologic by 26.1% in the 2nd quarter. Black Creek Investment Management Inc. now owns 4,027,829 shares of the medical equipment provider’s stock worth $262,453,000 after purchasing an additional 832,444 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Hologic

In other news, Director Christiana Stamoulis sold 7,402 shares of the business’s stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the transaction, the director directly owned 47,336 shares of the company’s stock, valued at $3,458,841.52. The trade was a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the sale, the chief executive officer directly owned 1,234,624 shares of the company’s stock, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.88% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.